Engineering Cas9: next generation of genomic editors.
Appl Microbiol Biotechnol
; 108(1): 209, 2024 Feb 14.
Article
en En
| MEDLINE
| ID: mdl-38353732
ABSTRACT
The Cas9 endonuclease of the CRISPR/Cas type IIA system from Streptococcus pyogenes is the heart of genome editing technology that can be used to treat human genetic and viral diseases. Despite its large size and other drawbacks, S. pyogenes Cas9 remains the most widely used genome editor. A vast amount of research is aimed at improving Cas9 as a promising genetic therapy. Strategies include directed evolution of the Cas9 protein, rational design, and domain swapping. The first generation of Cas9 editors comes directly from the wild-type protein. The next generation is obtained by combining mutations from the first-generation variants, adding new mutations to them, or refining mutations. This review summarizes and discusses recent advances and ways in the creation of next-generation genomic editors derived from S. pyogenes Cas9. KEY POINTS ⢠The next-generation Cas9-based editors are more active than in the first one. ⢠PAM-relaxed variants of Cas9 are improved by increased specificity and activity. ⢠Less mutagenic and immunogenic variants of Cas9 are created.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Genómica
/
Sistemas CRISPR-Cas
Límite:
Humans
Idioma:
En
Revista:
Appl Microbiol Biotechnol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Rusia